BridgeBio Oncology Therapeutics Ord Shs

Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

BridgeBio Oncology Therapeutics Ord Shs generated -113.89M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

BridgeBio Oncology Therapeutics Ord Shs's operating cash flow increased by -14811.10% year over year.

Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

BridgeBio Oncology Therapeutics Ord Shs spent 606.00K on capital expenditures in the most recent quarter。

Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

BridgeBio Oncology Therapeutics Ord Shs used 383.40M in financing activities in the latest quarter.

Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

Free cash flow was -114.50M reflecting a -14890.44% change from the previous year.